ClinicalTrials.gg
WithdrawnNCT03686657RESILIENCEUpdated Jul 16, 2026

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

A Phase 1/2 interventional study of Metformin and Val, Cel and Met XR Low in Type 2 Diabetes, High Blood Pressure and Arthritis, sponsored by ARKAY Therapeutics. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by ARKAY Therapeutics · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Clinical stage asset and the sponsorship have been acquired by Myopharm Limited.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing valsartan in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. Valsartan · Diabetes Mellitus, Type 2.

Enrollment
14th of 15
0 · median 81
Started
2026
with 2 others
Phase 1/2
Only one
of the 15
Registered
11th of 15
by date
Lead sponsor
1 of 15
ARKAY Therapeutics

Among the 15 studies testing valsartan in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 3 that started in 2026, is the only one in phase 1/2, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing valsartan in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing valsartan in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise over 26 weeks of treatment.

Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy.

Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.

Read the detailed description

PRIMARY:

In patients with type 2 diabetes with inadequate glycemic control with metformin monotherapy:

Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy. Improvements in glycemic, inflammatory and atherogenic parameters including beta cell function relative to adult healthy volunteers with normal glucose tolerance (NGT) treated with placebo for 26 weeks will also be assessed. An interim study assessment will also be performed after 12 weeks of treatment.

Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.

03

Conditions studied

  • Type 2 Diabetes
  • High Blood Pressure
  • Arthritis
  • Obesity

Keywords

  • Diabetes
  • Obesity
  • FPG
  • Beta cell function index
  • HbA1c
  • Atherogenic index
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, Age: >18 to 70 years at the time of screening visit.
  2. Women of (WOCBP) must have negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent of HCG) within 24 hours prior to the start of the study.
  3. Women must not be breastfeeding.
  4. ≥8.0
  5. Patients with inadequate blood glucose control with Metformin defined as a central laboratory glycosylated (HbA1c) >8.0 and \<10.5 obtained at the screening visit. Metformin-HCl monotherapy was inadequate 3 months prior to the study as indicated by the lack of decrease and/or an increase in the A1c level.

    Newly diagnosed drug naïve patients as defined by HbA1c>7.0 at the screening visit. Drug naïve subjects diagnosed with type 2 diabetes within 6 months of diagnosis will be considered and selected.

    About half the patients are expected to be newly diagnosed in the study.

  6. Drug naive as well as osteoarthritis patients with Type 2 diabetes receiving a non-aspirin pain reliever (e.g. acetaminophen) or an NSAID (e.g. Naproxen).
  7. Max/maintenance dose Metformin. Subjects should have been taking the same daily dose of metformin for at least 8 weeks prior to the enrollment visit and subjects not receive these other antihyperglycemic medications within the 12 weeks prior to screening (except for short-term use of insulin [≤7 days] during concomitant illness or other stress).
  8. Patients with >25% AIRg at 2 minutes and 10 minutes.
  9. RAS blocker naïve patients
  10. 2-Hour OGTT ≥200 mg/dL
  11. FPG ≥140 mg/dL
  12. ≥30
  13. Impaired first phase and second phase of insulin secretion
  14. BP ≥140/90 mm Hg (These patients might be on an anti-hypertensive drug)
  15. Non-fasting laboratory glucose >200 mg/dL with symptoms of polydipsia, polyuria and/or Polyphagia
  16. ≥ 60 ml/min/1.73m2

Exclusion criteria

Exclusion Criteria:

  1. Age >70
  2. Patients with Type 1 diabetes, Screen for GAD (Glutamic acid decarboxylase) antibodies at the time of screening visit. To rule out latent diabetes in adults (LADA), screening for other diabetes-related antibodies, such as insulinoma-associated protein (IA-2 and IA-2 beta), zinc transporter-8 (ZnT8), islet cell antibodies (ICA) or insulin autoantibody (IAA) will also be considered.
  3. Pregnant women
  4. Patients with a history of Ketoacidosis.
  5. Subjects at serious risk of gastrointestinal (GI) adverse events (e.g. current or recent history of GI bleeding ulceration, or perforation).
  6. Subjects with a planned radiologic study with intravenous contrast, surgery, or other planned procedures that may predispose them to metformin-associated lactic acidosis.
  7. Insulin dependent: \<25% Beta-cell function: AIRg (Acute insulin response to glucose after 2 min and 10 min after glucose injection) INSULIN DEPENDENT STATE.
  8. Patients with a history of uncontrolled hyperglycemia >15.0 mmol/L (280 mg/dL) after an overnight fast that required rescue therapy.
  9. Patients with uncontrolled hyperglycemia >15.0 mmol/L (280 mg/dL) after an overnight fast that required rescue therapy during week 1-3 Metformin-HCl monotherapy or RK-01 therapy.
  10. , impaired kidney function \< 60 ml/min/1.73m2.
  11. Poor metabolizers of Cyp450 2C9 to avoid very high concentration (Since Cytochrome 450 2C9 is responsible for the metabolism of both Valsartan and Celecoxib, patients who are known or suspected to be poor Cyp450 2C9 metabolizers based on previous history will be excluded from the study).
  12. Any of the following cardiovascular (CV)/Vascular diseases within 3 months of the enrollment visit:

    1. Myocardial infarction (MI)
    2. Cardiac surgery or revascularization (coronary artery bypass surgery, Coronary Artery Bypass Graft [(CABG]/Percutaneous transluminal coronary angioplasty (PTCA)].
    3. Unstable angina
    4. Unstable congestive heart failure (CHF)
    5. (TIA) or significant cerebrovascular disease
    6. Unstable or previously diagnosed arrhythmia
    7. Congestive heart failure, defined as (NYHA) Class III and IV, unstable or acute heart failure and/or known of ≤40%.
    8. Acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to the .
  13. Previous bariatric surgery
  14. Treatment with anti-obesity drugs within 3 months prior to consent
  15. Patients with
  16. Patients with liver disease
  17. Patients with renal disease
  18. Patients with autoimmune diseases e.g. Lupus, Psoriasis
  19. Patients with /AIDS
  20. Patients with diabetes-related complications
  21. Patients with Hematological and Oncological Diseases/Conditions
  22. \<11.0 g/dL (110 g/L) for men; hemoglobin \<10.0 g/dL (100 g/L) for women
  23. Patients with chronic disease e.g. Cancer, Epilepsy, Alzheimer, Parkinson, Asthma
  24. Abnormal free T4
  25. Patients with serious infection
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • No intervention
    Healthy adults with NGT

    Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.

  • Active comparator
    Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin

    Patients receive metformin once daily

    Drug: Metformin

  • Experimental
    RK-01 Low

    Patients receive valsartan, celecoxib and metformin (low dose) once daily

    Drug: Val, Cel and Met XR Low

  • Experimental
    RK-01 High

    Patients receive valsartan, celecoxib and metformin (high dose) once daily

    Drug: Val, Cel and Met XR High

Interventions

  • 1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks

    Also known as: Glucophage, Glucophage XR

  • DrugVal, Cel and Met XR Low

    Drug page: Valsartan

    500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.

    Also known as: Diovan, Celebrex, Glucophage XR, RK-01

  • DrugVal, Cel and Met XR High

    Drug page: Valsartan

    1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.

    Also known as: Diovan, Celebrex, Glucophage XR, RK-01

06

What researchers measure

Primary outcomes

  1. Change in glycosylated Hemoglobin (HbA1c) for metformin background patients

    Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline is calculated as the week 26 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage, the change from baseline is also a percentage.

    Time frame: Baseline and 26 weeks

  2. Change in glycosylated Hemoglobin (HbA1c) for treatment naive patients

    Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline is calculated as the week 26 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage, the change from baseline is also a percentage.

    Time frame: Baseline and 26 weeks

  3. Change from baseline in acute insulin response to glucose (AIRg) for metformin background patients

    Change in baseline in acute insulin response to glucose at week 26

    Time frame: Baseline and 26 weeks

  4. Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients

    Change in baseline in acute insulin response to glucose at week 26

    Time frame: Baseline and 26 weeks

Secondary outcomes

  1. Change in glycosylated Hemoglobin (HbA1c) to <7.0%

    Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline is calculated as the week 26 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage, the change from baseline is also a percentage. Percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \<7.0%.

    Time frame: Baseline and 26 weeks

  2. Change from baseline in Body weight

    Change in body weight at week 26

    Time frame: Baseline and 26 weeks

  3. Change from baseline in fasting plasma glucose

    Change in baseline in fasting plasma glucose at week 26

    Time frame: Baseline and 26 weeks

  4. Change from baseline in Beta-cell function Index

    Change in baseline in beta cell function index at week 26. Beta-cell function Index is a measure of their capacity to respond to elevated blood glucose levels

    Time frame: Baseline and 26 weeks

  5. Change from baseline in insulin sensitivity index (ISI or Si)

    Change in baseline in insulin sensitivity at week 26

    Time frame: Baseline and 26 weeks

  6. Change from baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) ratio

    Change in baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) at week 26. GA:HbA1c ratio provides a measure of post-prandial excursion

    Time frame: Baseline and 26 weeks

  7. Change from baseline in HOMA2-b%

    Change in baseline in HOMA of Beta-cell function index at week 26

    Time frame: Baseline and 26 weeks

  8. Change from baseline in HOMA-IR

    Change in baseline in HOMA-IR at week 26. HOMA-IR is a measure of insulin resistance.

    Time frame: Baseline and 26 weeks

  9. Leptin/Adiponectin ratio

    Change in baseline in Leptin/Adiponectin ratio. Indicator of insulin resistance

    Time frame: Baseline and 26 weeks

  10. Change from baseline in Atherogenic Index (AI)

    Change in baseline in Atherogenic Index at week 26. Atherogenic Index (AI) is a predictor of cardiovascular risk

    Time frame: Baseline and 26 weeks

  11. Change from baseline in glycosylated albumin (GA)

    Change in baseline in glycosylated albumin (GA) at week 26

    Time frame: Baseline and 26 weeks

  12. Change from baseline in Leptin

    Change in baseline in Leptin at week 26

    Time frame: Baseline and 26 weeks

  13. Change from baseline in Adiponectin

    Change in baseline in Adiponectin at week 26

    Time frame: Baseline and 26 weeks

07

Study locations

1 site
  • Albany Medical College
    Albany, New York 12206, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Study results will be published on clinicaltrials.gov as well as a medical journal. We also plan to present the results at a conference such as American Diabetes Association's Scientific Sessions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2018
First posted
Sep 27, 2018
StartEst.
Dec 10, 2026
Primary completionEst.
Dec 26, 2030
CompletionEst.
Jan 31, 2031
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03686657
Lead sponsor
ARKAY Therapeutics
Collaborators
Albany Medical College, Myopharm Limited
Responsible party
Sponsor
First posted
Sep 27, 2018
Start date
Dec 10, 2026 (estimated)
Primary completion
Dec 26, 2030 (estimated)
Completion
Jan 31, 2031 (estimated)
Last update
Jul 16, 2026

Study contacts

Ravi Kumar, Ph.D.
study director · ARKAY Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion